3 results on '"Sager, Hendrik B."'
Search Results
2. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
- Author
-
Aytekin, Alp, Ndrepepa, Gjin, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Lahu, Shqipdona, Richardt, Gert, Witzenbichler, Bernhard, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J., Valina, Christian, Kufner, Sebastian, Liebetrau, Christoph, Hamm, Christian W., Xhepa, Erion, Hapfelmeier, Alexander, and Sager, Hendrik B.
- Subjects
- *
PERCUTANEOUS coronary intervention , *MYOCARDIAL infarction , *TICAGRELOR , *PRASUGREL , *MEDICAL equipment , *RESEARCH , *STROKE , *TIME , *RESEARCH methodology , *MEDICAL care , *NEUROTRANSMITTERS , *SURGICAL stents , *MEDICAL cooperation , *EVALUATION research , *CARDIOVASCULAR system , *MEDICAL care research , *DISEASE relapse , *TREATMENT effectiveness , *RISK assessment , *COMPARATIVE studies , *RANDOMIZED controlled trials , *DRUGS , *PLATELET aggregation inhibitors , *HEMORRHAGE - Abstract
Background: Data on the comparative efficacy and safety of ticagrelor versus prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention are limited. We assessed the efficacy and safety of ticagrelor versus prasugrel in a head-to-head comparison in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.Methods: In this prespecified subgroup analysis, we included 1653 patients with ST-segment-elevation myocardial infarction randomized to receive ticagrelor or prasugrel in the setting of the ISAR REACT-5 trial (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5). The primary end point was the incidence of death, myocardial infarction, or stroke at 1 year after randomization. The secondary end point was the incidence of bleeding defined as BARC (Bleeding Academic Research Consortium) type 3 to 5 bleeding at 1 year after randomization.Results: The primary end point occurred in 83 patients (10.1%) in the ticagrelor group and in 64 patients (7.9%) in the prasugrel group (hazard ratio, 1.31 [95% CI, 0.95-1.82]; P=0.10). One-year incidence of all-cause death (4.9% versus 4.7%; P=0.83), stroke (1.3% versus 1.0%; P=0.46), and definite stent thrombosis (1.8% versus 1.0%; P=0.15) did not differ significantly in patients assigned to ticagrelor or prasugrel. One-year incidence of myocardial infarction (5.3% versus 2.8%; hazard ratio, 1.95 [95% CI, 1.18-3.23]; P=0.010) was higher with ticagrelor than with prasugrel. BARC type 3 to 5 bleeding occurred in 46 patients (6.1%) in the ticagrelor group and in 39 patients (5.1%) in the prasugrel group (hazard ratio, 1.22 [95% CI, 0.80-1.87]; P=0.36).Conclusions: In patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention, there was no significant difference in the primary end point between prasugrel and ticagrelor. Ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01944800. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
3. Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
- Author
-
Valina, Christian, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Aytekin, Alp, Richardt, Gert, Witzenbichler, Bernhard, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J, Kufner, Sebastian, Liebetrau, Christoph, Hamm, Christian W, Xhepa, Erion, Hapfelmeier, Alexander, Sager, Hendrik B, Wustrow, Isabel, and Joner, Michael
- Subjects
- *
TREATMENT of acute coronary syndrome , *RESEARCH , *RESEARCH methodology , *NEUROTRANSMITTERS , *ACUTE coronary syndrome , *EVALUATION research , *MEDICAL cooperation , *CORONARY angiography , *COMPARATIVE studies , *RANDOMIZED controlled trials , *PLATELET aggregation inhibitors , *DRUGS , *DISEASE complications - Abstract
Background: Current guidelines recommend intensified platelet inhibition by prasugrel or ticagrelor in patients with unstable angina (UA) or non-ST-segment elevation (NSTE) myocardial infarction (MI).Objectives: This study sought to investigate the benefits and risks of ticagrelor as compared with prasugrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) and planned invasive management.Methods: This post hoc analysis combines the pre-specified subgroups of UA and NSTEMI of the randomized ISAR-REACT 5 trial. It included 1,179 patients assigned to ticagrelor and 1,186 assigned to prasugrel. Ticagrelor was started immediately after randomization and prasugrel after coronary angiography. The primary endpoint was a composite of death, MI, or stroke during 1-year follow-up, and the safety endpoint was Bleeding Academic Research Consortium class 3-5.Results: The primary endpoint was reached in 101 (8.7%) patients in the ticagrelor and in 73 (6.3%) patients in the prasugrel group (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.04 to 1.90). The HR for all-cause death was 1.43 (95% CI: 0.93 to 2.21) and that for MI 1.43 (95% CI: 0.94 to 2.19). The safety endpoint occurred in 49 (5.2%) patients in the ticagrelor and in 41 (4.7%) patients in the prasugrel group (HR: 1.09; 95% CI: 0.72 to 1.65). Landmark analysis revealed persistence of the efficacy advantage with prasugrel after the first month.Conclusions: In patients with NSTE-ACS, we found that prasugrel was superior to ticagrelor in reducing the combined 1-year risk of death, MI, and stroke without increasing the risk of bleeding. Due to the post hoc nature of the analysis, these findings need confirmation by further studies. (Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome; NCT01944800). [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.